You are here:Home-Inhibitors & Agonists-Antibiotics and Antivirals-Fungal

Request The Product List ofFungal Fungal

Cat. No. Product Name CAS No. Information
PC-63228

ML316

2206822-41-3

ML316 is a specific antifungal agent that fungal-selectively inhibits the mitochondrial phosphate carrier Mir1, exhibits potent antifungal activity against the moderatelyazole-resistant C. albicans strain CaCi-2 with MIC of 0.05 ug/ml; kills drug-resistant Candida species at nanomolar concentrations; diminishes mitochondrial oxygen consumption, resulting in an unusual metabolic catastrophe marked by citrate accumulation and death in respiring yeast; reduces fungal burden and enhances azole activity in mouse model of azole-resistant oropharyngeal candidiasis.

PC-63050

Butenafine hydrochloride

101827-46-7

Butenafine is a synthetic benzylamine antifungal that inhibits the synthesis of ergosterol by inhibiting squalene epoxidase; displays superior activity against Candida albicans than terbinafine and naftifine; demonstrates low MICs against Cryptococcus and Aspergillus.

Fungal Infection

Approved

PC-62617

APX001

936339-60-5

APX001 (APX 001A;E1210) is a novel broad-spectrum antifungal agent that inhibits the fungal protein Gwt1, demonstrates significantly acitive MIC50 and MIC90 values of 0.004 and 0.031 ug/ml (16 strains of C. auris); inhibits the inositol acylation activity of C. albicans Gwt1p and A. fumigatus Gwt1p with IC50 of 0.3 to 0.6 uM but has no inhibitory activity against human Pig-Wp; shows significant efficacy in murine model of disseminated C. auris infection, and log reduction in CFU counts in kidney, lung, and brain tissue.

Fungal Infection

Phase 1 Clinical

PC-35452

Fosmanogepix

2091769-17-2 Fosmanogepix (APX001 prodrug) is a novel antifungal agent, the prodrug form of APX001, which inhibits the fungal protein Gwt1.
PC-62615

PC945

1931946-73-4 PC945 is a novel broad spectrum antifungal agent that potently inhibits Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) with IC50 of 0.23 and 0.22 uM, respectively; shows MIC values 0.032 to >8 ug/ml against 96 clinically isolated A. fumigatus strains, demonstrates activity against itraconazole-susceptible and -resistant A. fumigatus growth with IC50 of 0.0012 to 0.034 ug/ml; PC945 is a broad spectrum of pathogenic fungi with MIC 0.0078 to 2 ug/ml, and exhibits activity in vivo.

Fungal Infection

Phase 1 Clinical

PC-62607

PC1244

2046185-88-8 PC1244 is a long acting fungicidal azole that targets A. fumigatus CYP51A and CYP51B, inhibits ergosterol synthesis in A. fumigatus with IC50 of 8 nM; demonstrates potent antifungal activities against clinical A. fumigatus isolates with a MIC range of 0.016-0.25 ug/mL; PC1244 is also effective against a broad spectrum of pathogenic fungi (MIC= <0.0078-2 μg/ml), especially on Aspergillus terreus, Trichophyton rubrum, Candida albicans; shows fungicidal activity (MFC=2 μg/ml), 8-fold more potent than voriconazole; shows superior in vivo effects in immunocompromised mice.
PC-61753

VT-1161

1340593-59-0 VT-1161 is a potent, highly-selective, and oral fungal CYP51 inhibitor with Kd of ≤ 39 nM; demonstrates >2,000-fold selectivit over human CYP51, weakly inhibits human CYP2C9, CYP2C19, and CYP3A4; exhibits excellent potency against key yeast and dermatophyte strains.

Fungal Infection

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com